Heart Failure Spotlight: Jardiance® (empagliflozin) tablets: The Impact of EMPA-REG OUTCOME
American College of Cardiology American College of Cardiology
23.6K subscribers
20,557 views
0

 Published On Oct 29, 2021

This program reviews efficacy and safety data from the EMPA-REG OUTCOME trial. It provides information on JARDIANCE initiation and dosing, as well as guidance for monitoring patients on JARDIANCE.

Speaker:
Narendra Singh, MD, FRCPC, FCCS, FACC, FAHA
Clinical Assistant Professor, Medical College of Georgia at Augusta University
Director of Clinical Research, NSC Cardiology
Johns Creek, Georgia

Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC
#heartfailure #ACC21

show more

Share/Embed